Ivantis has reported the six-month results from its multicentre, prospective and international Hydrus I study, which was designed to evaluate the safety and efficacy of the Hydrus intracanalicular implant in two surgical settings.

Hydrus intracanalicular implant, roughly the size of an eyelash, is placed through a minimally invasive, microsurgical procedure, and is designed to reduce eye pressure by re-establishing the patient’s conventional outflow pathway.

The Hydrus device relies on a twofold mechanism that creates a relatively large opening through the traditional source of flow blockage, and then dilates and scaffolds the critical quadrant of the outflow pathway through which fluid exits the eye.

The study involved 69 patients. Twenty-nine received the Hydrus device in conjunction with cataract surgery (combination surgery group), while 40 patients received the device alone (device-only surgery group).

The six-month follow-up included measurements of change in IOP and change of medication burden to patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The data from the study showed that in the combination surgery group, the patients’ average IOP decreased from 21.1mmHg before surgery to 15.6mmHg at six months, and the medication burden reduced from an average of 2.1 to 0.4 eye drops per patient.

In the device-only surgery group, the average IOP decreased from 21.6mmHg before surgery to 16.9mmHg at six months, and average medication burden reduced from 1.7 to 0.6 eye drops per patient.

At a six-month follow-up, 85% of patients in the combination surgery group and 70% of device-only surgery patients were free of medication.